New drug BIIB142 tested in humans for the first time
NCT ID NCT07133828
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing the safety of a new drug called BIIB142 in 78 healthy adults. Participants receive either the drug or a placebo, in single or multiple doses, to see how the body handles it and whether it causes any side effects. The study is split into two parts: Part A tests a single dose, and Part B tests daily doses for 14 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BIIB142
- What could go wrong
- This is an early phase 1 trial in healthy volunteers, so it only tests safety and how the drug moves through the body. There is no disease being treated, so success here does not guarantee any future treatment benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PPD Development, LP
RECRUITINGLas Vegas, Nevada, 89113, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?